PRIME MEMBER EXCLUSIVE | 3 Months Free Trial
Auto-renews at INR 199/mo after 3 months. Cancel anytime. Offer ends 15 July, 2026.
Biotech Briefing for 03 June: Antibody Platform, Biotech Funding
Failed to add items
Add to cart failed.
Add to wishlist failed.
Remove from wishlist failed.
Follow podcast failed
Unfollow podcast failed
Biotech Briefing for 03 June: Antibody Platform, Biotech Funding
-
Narrated by:
-
Written by:
Biotech Briefing is a daily audio summary of actionable biotech innovation, research, regulation, markets, and society debates from r/biotechnology and r/biotech. This 2-story episode draws from biotech and moves through antibody platform, biotech funding.
1. Antibody Platform
May brought another wave of antibody-focused biotech deals, and the pattern is hard to miss: large drugmakers are still paying heavily for platforms that can make antibodies more targeted, more multifunctional, or easier to combine with other immune tools. The biggest signals came from Pfizer and Innovent, with a collaboration covering up to 12 antibody drugs, and Bristol Myers Squibb and Hengrui, with a 13-asset agreement spanning oncology, hematology, and immunology.
Source link
Discussion thread
Source subreddit: biotech
2. Biotech Funding
The White House is moving to change how federal science grants are approved, and the proposal could give political appointees more power over research funding decisions. Under the reported rule change, expert peer review would still happen, but it would become advisory, with senior appointees able to screen awards before money goes out.
Source link
Discussion thread
Source subreddit: biotech
That's it for this Biotech Briefing.